262 related articles for article (PubMed ID: 20466363)
21. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
[TBL] [Abstract][Full Text] [Related]
22. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
Freedman M; Kaunitz AM; Reape KZ; Hait H; Shu H
Menopause; 2009; 16(4):735-41. PubMed ID: 19252451
[TBL] [Abstract][Full Text] [Related]
23. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
24. Conjugated estrogens (Premarin) vaginal cream.
Med Lett Drugs Ther; 2009 Feb; 51(1306):14-5. PubMed ID: 19229162
[TBL] [Abstract][Full Text] [Related]
25. [Safety of promestriene capsule used in postmenopausal atrophic vaginitis].
Sun AJ; Lin SQ; Jing LH; Wang ZY; Ye JL; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Aug; 44(8):593-6. PubMed ID: 20003787
[TBL] [Abstract][Full Text] [Related]
26. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
Simon JA; Reape KZ; Wininger S; Hait H
Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
[TBL] [Abstract][Full Text] [Related]
27. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women.
Mandel FP; Geola FL; Meldrum DR; Lu JH; Eggena P; Sambhi MP; Hershman JM; Judd HL
J Clin Endocrinol Metab; 1983 Jul; 57(1):133-9. PubMed ID: 6304131
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
[TBL] [Abstract][Full Text] [Related]
29. Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J; Lethaby A; Kennedy R
Cochrane Database Syst Rev; 2003; (4):CD001500. PubMed ID: 14583935
[TBL] [Abstract][Full Text] [Related]
30. By the way, doctor. My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree?
Robb-Nicholson C
Harv Womens Health Watch; 2007 Nov; 15(3):7. PubMed ID: 18225330
[No Abstract] [Full Text] [Related]
31. Atrophic vaginitis.
Stika CS
Dermatol Ther; 2010; 23(5):514-22. PubMed ID: 20868405
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women.
Zimmermann H; Koytchev R; Mayer O; Börner A; Mellinger U; Breitbarth H
Arzneimittelforschung; 1998 Sep; 48(9):941-7. PubMed ID: 9793623
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
34. A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream.
Bhamra RK; Margolis MB; Liu JH; Hendy CH; Jenkins RG; DiLiberti CE
Menopause; 2011 Apr; 18(4):393-9. PubMed ID: 21107298
[TBL] [Abstract][Full Text] [Related]
35. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women.
Yasui T; Uemura H; Umino Y; Takikawa M; Saito S; Kuwahara A; Matsuzaki T; Maegawa M; Furumoto H; Miura M; Irahara M
Maturitas; 2005 Jan; 50(1):19-29. PubMed ID: 15590210
[TBL] [Abstract][Full Text] [Related]
36. Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J; Lethaby A; Kennedy R
Cochrane Database Syst Rev; 2006 Oct; (4):CD001500. PubMed ID: 17054136
[TBL] [Abstract][Full Text] [Related]
37. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.
Santen RJ
Climacteric; 2015 Apr; 18(2):121-34. PubMed ID: 25327484
[TBL] [Abstract][Full Text] [Related]
38. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis.
Marx P; Schade G; Wilbourn S; Blank S; Moyer DL; Nett R
Maturitas; 2004 Jan; 47(1):47-54. PubMed ID: 14706765
[TBL] [Abstract][Full Text] [Related]
39. [Postmenopausal atrophic colpitis--its local treatment with low-dose estradiol].
Rachev E
Akush Ginekol (Sofiia); 1995; 34(1):41-2. PubMed ID: 7485806
[No Abstract] [Full Text] [Related]
40. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women.
Wakatsuki A; Okatani Y; Ikenoue N; Shinohara K; Watanabe K; Fukaya T
Circulation; 2003 Aug; 108(7):808-13. PubMed ID: 12900341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
